High Interest in Preexposure Prophylaxis Among Men Who Have Sex With Men at Risk for HIV Infection: Baseline Data From the US PrEP Demonstration Project

BACKGROUND:Preexposure prophylaxis (PrEP) is the first biomedical intervention with proven efficacy to reduce HIV acquisition in men who have sex with men (MSM) and transgender women. Little is known about levels of interest and characteristics of individuals who elect to take PrEP in real-world cli...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of acquired immune deficiency syndromes (1999) Vol. 68; no. 4; pp. 439 - 448
Main Authors:	Cohen, Stephanie E, Vittinghoff, Eric, Bacon, Oliver, Doblecki-Lewis, Susanne, Postle, Brian S, Feaster, Daniel J, Matheson, Tim, Trainor, Nikole, Blue, Robert W, Estrada, Yannine, Coleman, Megan E, Elion, Richard, Castro, Jose G, Chege, Wairimu, Philip, Susan S, Buchbinder, Susan, Kolber, Michael A, Liu, Albert Y
Format:	Journal Article
Language:	English
Published:	United States Copyright Wolters Kluwer Health, Inc. All rights reserved 01-04-2015 Lippincott Williams & Wilkins Ovid Technologies
Subjects:	Adenine - analogs & derivatives Adenine - therapeutic use Adolescent Adult Anti-HIV Agents - therapeutic use Chemoprevention - methods Chemoprevention - utilization Cohort Studies Community health care Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Disease prevention Disease Transmission, Infectious - prevention & control Emtricitabine Health risk assessment HIV HIV Infections - prevention & control HIV Infections - transmission Homosexuality, Male Human immunodeficiency virus Humans Longitudinal Studies Male Mens health Organophosphonates - therapeutic use Patient Acceptance of Health Care Pre-Exposure Prophylaxis - methods Pre-Exposure Prophylaxis - utilization Prospective Studies Sexually transmitted diseases STD Tenofovir Transgender persons United States Young Adult United States Miami Florida San Francisco California
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	BACKGROUND:Preexposure prophylaxis (PrEP) is the first biomedical intervention with proven efficacy to reduce HIV acquisition in men who have sex with men (MSM) and transgender women. Little is known about levels of interest and characteristics of individuals who elect to take PrEP in real-world clinical settings. METHODS:The US PrEP Demonstration Project is a prospective open-label cohort study assessing PrEP delivery in municipal sexually transmitted disease clinics in San Francisco and Miami and a community health center in Washington, DC. HIV-uninfected MSM and transgender women seeking sexual health services at participating clinics were assessed for eligibility and offered up to 48 weeks of emtricitabine/tenofovir for PrEP. Predictors of enrollment were assessed using a multivariable Poisson regression model, and characteristics of enrolled participants are described. RESULTS:Of 1069 clients assessed for participation, 921 were potentially eligible and 557 (60.5%) enrolled. In multivariable analyses, participants from Miami (adjusted Relative Risk [aRR]1.53; 95% confidence interval [CI]1.33 to 1.75) or DC (aRR1.33; 95% CI1.2 to 1.47), those who were self-referred (aRR1.48; 95% CI1.32 to 1.66), those with previous PrEP awareness (aRR1.56; 95% CI1.05 to 2.33), and those reporting >1 episode of anal sex with an HIV-infected partner in the last 12 months (aRR1.20; 95% CI1.09 to 1.33) were more likely to enroll. Almost all (98%) enrolled participants were MSM, and at baseline, 63.5% reported condomless receptive anal sex in the previous 3 months. CONCLUSIONS:Interest in PrEP is high among a diverse population of MSM at risk for HIV infection when offered in sexually transmitted disease and community health clinics.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1525-4135 1944-7884
DOI:	10.1097/QAI.0000000000000479